JP2011514358A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011514358A5 JP2011514358A5 JP2010550703A JP2010550703A JP2011514358A5 JP 2011514358 A5 JP2011514358 A5 JP 2011514358A5 JP 2010550703 A JP2010550703 A JP 2010550703A JP 2010550703 A JP2010550703 A JP 2010550703A JP 2011514358 A5 JP2011514358 A5 JP 2011514358A5
- Authority
- JP
- Japan
- Prior art keywords
- patent document
- bile salts
- application publication
- taurocholate
- patent application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003833 bile salt Substances 0.000 description 5
- 229940093761 bile salts Drugs 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- WBWWGRHZICKQGZ-HZAMXZRMSA-N taurocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 WBWWGRHZICKQGZ-HZAMXZRMSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- -1 alkaloid compounds Chemical class 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 210000005178 buccal mucosa Anatomy 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 1
- 229960003708 sumatriptan Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6941408P | 2008-03-14 | 2008-03-14 | |
| PCT/US2009/001626 WO2009114192A2 (en) | 2008-03-14 | 2009-03-13 | Enhanced transmucosal composition and dosage form |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011514358A JP2011514358A (ja) | 2011-05-06 |
| JP2011514358A5 true JP2011514358A5 (enExample) | 2013-05-16 |
Family
ID=41065734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010550703A Pending JP2011514358A (ja) | 2008-03-14 | 2009-03-13 | 改良された経粘膜組成物および剤形 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20110021583A1 (enExample) |
| EP (1) | EP2265250A2 (enExample) |
| JP (1) | JP2011514358A (enExample) |
| CA (1) | CA2717984C (enExample) |
| MX (1) | MX2010009961A (enExample) |
| WO (1) | WO2009114192A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3316865A4 (en) | 2015-07-02 | 2019-01-23 | Civitas Therapeutics, Inc. | TRIPTAN POWDER FOR PULMONARY ADMINISTRATION |
| CA3166250A1 (en) * | 2020-02-05 | 2021-08-12 | Gregory G. Plucinski | Drug products for intranasal administration and uses thereof |
| WO2026050777A2 (en) * | 2024-09-01 | 2026-03-05 | Sandipkumar Patel | Stable liquid formulations of frovatriptan |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4968507A (en) * | 1984-06-20 | 1990-11-06 | Merck & Co., Inc. | Controlled porosity osmotic pump |
| JPH11292787A (ja) * | 1995-08-15 | 1999-10-26 | Asahi Chem Ind Co Ltd | 生理活性ペプチドを含有する経粘膜投与製剤 |
| US6255502B1 (en) * | 1996-07-11 | 2001-07-03 | Farmarc Nederland B.V. | Pharmaceutical composition containing acid addition salt of basic drug |
| TWI243687B (en) * | 1998-04-21 | 2005-11-21 | Teijin Ltd | Pharmaceutical composition for application to mucosa |
| US6210699B1 (en) * | 1999-04-01 | 2001-04-03 | Watson Pharmaceuticals, Inc. | Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity |
| AR026072A1 (es) * | 1999-10-20 | 2002-12-26 | Nycomed Gmbh | Composicion farmaceutica que contiene ciclesonida para aplicacion a la mucosa |
| AU2023401A (en) * | 1999-12-01 | 2001-06-12 | Natco Pharma Limited | A rapid acting freeze dired oral pharmaceutical composition for treating migraine |
| US20020147232A1 (en) * | 2000-05-26 | 2002-10-10 | Claus Sundgreen | Pharmaceutical compositions comprising desglymidodrine as an active drug substance |
| WO2004093917A2 (en) * | 2003-04-22 | 2004-11-04 | Nastech Pharmaceutical Company Inc. | Intranasal administration of triptans |
| US20060002989A1 (en) * | 2004-06-10 | 2006-01-05 | Ahmed Salah U | Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same |
| US20060193908A1 (en) * | 2004-11-09 | 2006-08-31 | Burnside Beth A | Extended release formulations of poorly soluble antibiotics |
| WO2007096906A2 (en) * | 2006-02-27 | 2007-08-30 | Panacea Biotec Ltd. | Novel buccoadhesive compositions and process of preparation thereof |
-
2009
- 2009-03-13 WO PCT/US2009/001626 patent/WO2009114192A2/en not_active Ceased
- 2009-03-13 JP JP2010550703A patent/JP2011514358A/ja active Pending
- 2009-03-13 EP EP09719448A patent/EP2265250A2/en not_active Withdrawn
- 2009-03-13 MX MX2010009961A patent/MX2010009961A/es not_active Application Discontinuation
- 2009-03-13 CA CA2717984A patent/CA2717984C/en not_active Expired - Fee Related
-
2010
- 2010-08-23 US US12/860,978 patent/US20110021583A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6657454B2 (ja) | ブプレノルフィンの乱用抵抗性粘膜付着性送達デバイス | |
| JP2011515472A5 (enExample) | ||
| ES2745471T3 (es) | Formulaciones orales de liberación inmediata para quinazolinonas sustituidas | |
| CN105792847B (zh) | 急性骨髓性白血病(aml)的新型组合治疗 | |
| JP2013537891A5 (enExample) | ||
| JP2019513799A5 (enExample) | ||
| JP2008044951A5 (enExample) | ||
| JP2008523153A5 (enExample) | ||
| BR112013032122A2 (pt) | liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos | |
| JP2017530940A (ja) | Ｐｒｍｔ５阻害剤およびその使用 | |
| JP2009542657A5 (enExample) | ||
| JP2014528474A5 (enExample) | ||
| WO2007124250A3 (en) | Methods of treating hot flashes with formulations for transdermal or transmucosal application | |
| WO2008027854A3 (en) | Pharmaceutical compositions comprising hgh for oral delivery | |
| WO2006108405A3 (de) | Nanopartikel-wirkstoff-konjugate | |
| EP2765989B1 (en) | Methods and compositions for rapid transbuccal delivery of active agents | |
| AU2011329066A1 (en) | Controlled release mucoadhesive systems | |
| EA200802350A3 (ru) | Система доставки лекарств | |
| JP2020500864A5 (enExample) | ||
| FR2906140A1 (fr) | Forme galenique pour l'administration par voie trans-muqueuse de principes actifs | |
| CA3127926A1 (en) | Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa | |
| ES2383433T3 (es) | Formulación farmacéutica de apomorfina para administración bucal | |
| WO2011093818A3 (en) | Pharmaceutical compositions comprising salmeterol and fluticasone | |
| MY150820A (en) | Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance | |
| JP2015521647A5 (enExample) |